Medical Marijuana Inc. Moves Forward With Proof of Concept Study
Cannabis company works with Israel-based CRO
Medical Marijuana Inc. announced in late July 2017, that the San Diego, CA-based company’s AXIM Biotechnologies was working with an Israel-based contract research organization to begin a clinical proof of concept study (POC) with its cannabidiol and gabapentin chewing gum product to treat restless leg syndrome in patients.
There will be a randomized, double-blind, single-center, phase two trial to demonstrate the efficacy of AXIM’s chewing gum product. Thirty study subjects will be enrolled in Israel.
Restless leg syndrome (RLS), also called Willis-Ekbom disease, is when nocturnal sensorimotor symptoms occur. People with RLS have lower extremity muscle spasms while they are sleeping. This can disrupt their sleep and cause pain. Anywhere from around 4% to 14% of the U.S. population has this condition.
“We believe that advancements in clinical cannabinoid research may hold keys to helping people experience symptomatic relief from challenging and debilitating neurological disorders,” Stuart Titus, PhD, chief executive officer of Medical Marijuana, said in a news statement.
Medical Marijuana Inc. announced it is working with an Israel-based contract research organization to begin a clinical proof of concept study with its cannabidiol and gabapentin chewing gum product to treat restless leg syndrome in patients.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.